CG-0416 enhances GLP-1-mediated hepatic lipid oxidation while activating the IGF-1/Akt/FOXO3a axis to suppress muscle catabolism. 2. Oral Administration Potential With 92% oral bioavailability – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results